Total
0
Shares
Healthia (ASX:HLA) - CEO, Wesley Coote
CEO, Wesley Coote
Source: Healthia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthia (HLA) shares enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy
  • The ASX-lister estimates the family-owned physiotherapy business could bring in $2.13 million in additional revenue
  • Healthia will pay $1.3 million as upfront consideration and expects to complete the buy before the end of November
  • Healthia shares were up 10.3 per cent to trade at $1.99 at 1:52 pm AEST

Healthia (HLA) shares have enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy.

The ASX-lister announced to the market it had entered a binding agreement to acquire the family-owned and operated physiotherapy business, which provides physiotherapy and exercise physiology to adults and children.

The acquisition is tipped to bring in $2.13 million in additional revenue and contribute $0.36 million to earnings before interest, taxes, depreciation and amortisation (EBITDA).

Healthia will pay $1.3 million as upfront consideration for the business, including $0.32 million in clinic class shares.

It is expected the acquisition will be completed on or before November 30 2021, subject to property leases and customary conditions.

Healthia Managing Director Wesley Coote said the company was looking forward to bringing Rothwell Physiotherapy into the group.

“The addition of Rothwell Physiotherapy is in line with Healthia’s stated growth strategy and brings us one step closer to being the number one provider of physiotherapy services in Australia,” he said.

“We have a strong acquisition pipeline in place for this financial year underpinned by industry participants placing greater value on the support and stability that a larger group such as Healthia, can provide.”

Healthia shares were up 10.3 per cent to trade at $1.99 at 1:52 pm AEST.

HLA by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.